Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 887 results for score

  1. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

  2. Joint distraction for knee osteoarthritis without alignment correction (HTG381)

    Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.

  3. Percutaneous mitral valve annuloplasty (HTG225)

    Evidence-based recommendations on percutaneous mitral valve annuloplasty. This involves inserting a catheter into a large vein in the groin or neck and passing through to the heart. A device is placed into a large vein that sits next to the mitral valve to constrict the valve, with the aim of making it close properly.

  4. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

  5. Scleral expansion surgery for presbyopia (HTG43)

    Evidence-based recommendations on scleral expansion surgery for presbyopia. This involves making small incisions in the eye and inserting bands to stretch part of the sclera.

  6. Haemorrhoidal artery ligation (HTG218)

    Evidence-based recommendations on haemorrhoidal artery ligation. This involves tying the blood vessels and folding up the inside lining of the bowel to reduce blood supply to the haemorrhoids and make them shrink.

  7. Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

  8. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

  9. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

  10. Flexible endoscopic treatment of a pharyngeal pouch (HTG367)

    Evidence-based recommendations on flexible endoscopic treatment of a pharyngeal pouch. This involves improving swallowing by widening the neck of the pouch so that food does not collect in it.

  11. Endometrial cryotherapy for menorrhagia (HTG101)

    Evidence-based recommendations on endometrial cryotherapy for menorrhagia (heavy periods). This involves using cold temperatures to freeze and destroy the lining of the womb.

  12. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

  13. Radiofrequency ablation of the soft palate for snoring (HTG327)

    Evidence-based recommendations on radiofrequency ablation of the soft palate for snoring. This involves using an electrode device to puncture and send radiofrequency energy into the soft palate to scar and tighten it.

  14. Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (HTG122)

    Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.

  15. Selective dorsal rhizotomy for spasticity in cerebral palsy (HTG245)

    Evidence-based recommendations on selective dorsal rhizotomy for spasticity in cerebral palsy. This involves cutting nerves in the lower spine that are responsible for muscle rigidity.